First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group

Metastatic Breast ◽

Hormonal Treatment ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Breast Group

First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.515 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 515-515 ◽

Cited By ~ 31

Author(s):

R. Paridaens ◽

P. Therasse ◽

L. Dirix ◽

L. Beex ◽

M. Piccart ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Hormonal Treatment ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Breast Group

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial

British Journal of Cancer ◽

10.1038/sj.bjc.6603096 ◽

2006 ◽

Vol 94 (9) ◽

pp. 1233-1236 ◽

Cited By ~ 21

Author(s):

C Pacilio ◽

◽

A Morabito ◽

F Nuzzo ◽

A Gravina ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Treatment ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Single Centre ◽

Phase Iii Trial ◽

Line Chemotherapy

A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study

Annals of Oncology ◽

10.1093/annonc/mdw077 ◽

2016 ◽

Vol 27 (6) ◽

pp. 1020-1029 ◽

Cited By ~ 14

Author(s):

O. Trédan ◽

P. Follana ◽

I. Moullet ◽

C. Cropet ◽

S. Trager-Maury ◽

...

Keyword(s):

Breast Cancer ◽

Maintenance Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

OT2-01-02: First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase III Trial.

10.1158/0008-5472.sabcs11-ot2-01-02 ◽

2011 ◽

Author(s):

S Beslija ◽

T Brodowicz ◽

R Greil ◽

MJ Inbar ◽

Z Kahán ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Locally Recurrent

Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen

Cancer ◽

10.1002/1097-0142(19940115)73:2<354::aid-cncr2820730220>3.0.co;2-j ◽

1994 ◽

Vol 73 (2) ◽

pp. 354-361 ◽

Cited By ~ 43

Author(s):

Kenneth E. Gale ◽

Janet W. Andersen ◽

Douglass C. Tormey ◽

Edward G. Mansour ◽

Thomas E. Davis ◽

...

Keyword(s):

Breast Cancer ◽

Eastern Cooperative Oncology Group ◽

Metastatic Breast ◽

Hormonal Treatment ◽

Phase Iii ◽

Oncology Group ◽

Pharmacokinetics (PK) of Pertuzumab (P) With Trastuzumab (T) and Docetaxel (D) in HER2-Positive First-Line Metastatic Breast Cancer (MBC): Results From the Phase III Trial Cleopatra

Annals of Oncology ◽

10.1016/s0923-7534(20)32905-7 ◽

2012 ◽

Vol 23 ◽

pp. ix124-ix125 ◽

Cited By ~ 2

Author(s):

J. Cortes ◽

S. Swain ◽

I. Kudaba ◽

M. Hauschild ◽

T. Patel ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Faculty Opinions recommendation of AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717998592.793477025 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent

Safety and efficacy of first-line epirubicin–docetaxel (ED) versus epirubicin–cyclophosphamide (EC): A multicenter randomized phase III trial in metastatic breast cancer (MBC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.627 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 627-627 ◽

Cited By ~ 3

Author(s):

J.-U. Blohmer ◽

M. Hauschild ◽

J. Hilfrich ◽

A. Kleine-Tebbe ◽

S. Kuemmel ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Safety And Efficacy

Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.

10.1158/1538-7445.am2013-lb-177 ◽

2013 ◽

Author(s):

Zsuzsanna Kahán ◽

Lubos Petruzelka ◽

Alexandru Eniu ◽

Rodica Anghel ◽

Krassimir Koynov ◽

...

Keyword(s):

Breast Cancer ◽

Subgroup Analysis ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive

1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)

European Journal of Cancer ◽

10.1016/s0959-8049(11)70916-9 ◽

2011 ◽

Vol 47 ◽

pp. S176 ◽

Cited By ~ 2

Author(s):

D.W. Miles ◽

S.L. De Haas ◽

G. Romieu ◽

A. Chan ◽

L. Dirix ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Polymorphism Analysis ◽

First Line ◽